Large Insider Purchases
Institutional-Scale SEC Form 4 Buy Signals
The Signal of $1M+ Conviction
When a corporate executive invests more than $1,000,000 of their own capital into company shares, it represents the highest level of conviction. These seven-figure purchases reflect management's belief in the company's future value.
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-03-25 23:29 | 2021-03-23 | TIL | Instil Bio, Inc. | Curative Ventures V LLC | 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $20.00 | 450,000 | $9,000,000 | 37,980,073 | +1.2% |
| 2021-03-26 00:32 | 2021-03-23 | TIL | Instil Bio, Inc. | Vivo Capital IX, LLC | 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $20.00 | 300,000 | $6,000,000 | 12,486,787 | +2.5% |
| 2021-03-26 01:05 | 2021-03-23 | FNCH | Finch Therapeutics Group, Inc. | Haft Nicholas | Director | Biological Products, (No Diagnostic Substances) | BUY | $17.00 | 882,351 | $14,999,967 | 882,351 | +100.0% |
| 2021-03-25 21:52 | 2021-03-23 | PFSI | PennyMac Financial Services, Inc. | MFN Partners, LP | Director | Mortgage Bankers & Loan Correspondents | BUY | $62.42 | 344,322 | $21,493,130 | 1,216,597 | +39.5% |
| 2021-03-26 00:31 | 2021-03-23 | TIL | Instil Bio, Inc. | Shah Nimish P | Director | Biological Products, (No Diagnostic Substances) | BUY | $20.00 | 300,000 | $6,000,000 | 19,620 | +100.0% |
| 2021-03-26 00:30 | 2021-03-23 | TIL | Instil Bio, Inc. | Nielsen Jack | Director | Biological Products, (No Diagnostic Substances) | BUY | $20.00 | 300,000 | $6,000,000 | 12,486,787 | +2.5% |
| 2021-03-25 23:15 | 2021-03-25 | FTAI | FTAI Aviation Ltd. | TUCHMAN MARTIN | Director | Services-Miscellaneous Equipment Rental & Leasing | BUY | $25.00 | 800,000 | $20,000,000 | 800,000 | +100.0% |
| 2021-03-25 21:57 | 2021-03-23 | PFSI | PennyMac Financial Services, Inc. | NANJI FARHAD | Director | Mortgage Bankers & Loan Correspondents | BUY | $62.42 | 344,322 | $21,493,130 | 1,216,597 | +39.5% |
| 2021-03-25 18:14 | 2021-03-24 | PRTA | PROTHENA CORP PUBLIC LTD CO | EcoR1 Capital, LLC | 10% owner | Pharmaceutical Preparations | BUY | $20.75 | 875,000 | $18,156,250 | 11,034,280 | +8.6% |
| 2021-03-26 00:28 | 2021-03-23 | TIL | Instil Bio, Inc. | McGaughy R Kent Jr | Director | Biological Products, (No Diagnostic Substances) | BUY | $20.00 | 450,000 | $9,000,000 | 8,478,790 | +5.6% |
| 2021-03-26 01:01 | 2021-03-23 | FNCH | Finch Therapeutics Group, Inc. | Crestovo Investor LLC | Director, 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $17.00 | 735,294 | $12,499,998 | 12,641,441 | +6.2% |
| 2021-03-26 01:04 | 2021-03-23 | FNCH | Finch Therapeutics Group, Inc. | FERRANTE DOMENIC J | Director | Biological Products, (No Diagnostic Substances) | BUY | $17.00 | 102,941 | $1,749,997 | 636,195 | +19.3% |
| 2021-03-26 01:08 | 2021-03-23 | FNCH | Finch Therapeutics Group, Inc. | SMISEK JEFFERY A | Director | Biological Products, (No Diagnostic Substances) | BUY | $17.00 | 88,235 | $1,499,995 | 1,694,541 | +5.5% |
| 2021-03-26 02:41 | 2021-03-23 | GLHA | N/A | AUERBACH JONATHAN A G | Director, 10% owner | Other | BUY | $10.00 | 2,000,000 | $20,000,000 | 2,000,000 | +100.0% |
| 2021-03-26 00:29 | 2021-03-23 | N-A | N/A | BLACKROCK FINANCIAL MANAGEMENT INC/DE | 10% owner, Other | Other | BUY | $10.00 | 2,490,000 | $24,900,000 | 2,500,000 | +24,900.0% |
| 2021-03-24 23:17 | 2021-03-23 | SAII | N/A | Mithaq Capital SPC | 10% owner | Other | BUY | $10.50 | 2,299,854 | $24,148,467 | 5,556,669 | +70.6% |
| 2021-03-25 03:24 | 2021-03-22 | VEI | N/A | Blackstone Energy Partners II Q (Pub) L.P. | 10% owner | Other | BUY | $13.30 | 4,285,000 | $56,990,500 | 145,715 | +100.0% |
| 2021-03-25 03:22 | 2021-03-22 | VEI | N/A | Brix Investment LLC | 10% owner | Other | BUY | $13.30 | 4,285,000 | $56,990,500 | 145,715 | +100.0% |
| 2021-03-25 04:06 | 2021-03-24 | CRTX | Quince Therapeutics, Inc. | Lamond David | Director | Biological Products, (No Diagnostic Substances) | BUY | $33.77 | 50,000 | $1,688,500 | 1,847,109 | +2.8% |
| 2021-03-25 03:17 | 2021-03-22 | VEI | N/A | BLACKSTONE FAMILY GP LLC | 10% owner | Other | BUY | $13.30 | 4,285,000 | $56,990,500 | 145,715 | +100.0% |
| 2021-03-25 03:17 | 2021-03-22 | VEI | N/A | Blackstone Holdings III GP Management L.L.C. | 10% owner | Other | BUY | $13.30 | 4,285,000 | $56,990,500 | 145,715 | +100.0% |
| 2021-03-25 04:02 | 2021-03-22 | FPH | Five Point Holdings, LLC | Luxor Capital Group, LP | 10% owner | Real Estate | BUY | $8.26 | 181,305 | $1,497,670 | 173,644 | +100.0% |
| 2021-03-25 04:02 | 2021-03-22 | AIV | Apartment Investment and Management Company | CONSIDINE TERRY | Director - Director | Real Estate Investment Trusts | BUY | $5.72 | 300,000 | $1,717,260 | 600,000 | +100.0% |
| 2021-03-25 03:13 | 2021-03-22 | VEI | N/A | Vine Investment LLC | 10% owner | Other | BUY | $13.30 | 4,285,000 | $56,990,500 | 145,715 | +100.0% |
| 2021-03-25 00:15 | 2021-03-22 | MRUS | Merus N.V. | BVF PARTNERS L P/IL | 10% owner | Pharmaceutical Preparations | BUY | $22.75 | 79,500 | $1,808,625 | 435,121 | +22.4% |
| 2021-03-24 00:01 | 2021-03-22 | N/A | N/A | Owl Rock Feeder FIC ORCIC Equity LLC | 10% owner | Other | BUY | $9.26 | 1,295,896 | $11,999,997 | 2,595,896 | +99.7% |
| 2021-03-23 22:24 | 2021-03-19 | PFSI | PennyMac Financial Services, Inc. | MFN Partners, LP | Director | Mortgage Bankers & Loan Correspondents | BUY | $62.11 | 532,363 | $33,066,716 | 872,275 | +156.6% |
| 2021-03-24 00:02 | 2021-03-22 | N/A | N/A | Packer Craig | Director, Officer, 10% owner - CEO and President | Other | BUY | $9.26 | 1,295,896 | $11,999,997 | 2,595,996 | +99.7% |
| 2021-03-23 22:31 | 2021-03-19 | PFSI | PennyMac Financial Services, Inc. | NANJI FARHAD | Director | Mortgage Bankers & Loan Correspondents | BUY | $62.11 | 532,363 | $33,066,716 | 872,275 | +156.6% |
| 2021-03-23 19:44 | 2021-03-19 | TPGY | N/A | TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 10% owner | Other | BUY | $19.59 | 146,836 | $2,876,312 | 4,957,302 | +3.1% |
| 2021-03-24 00:03 | 2021-03-22 | N/A | N/A | Kirshenbaum Alan | Director, 10% owner | Other | BUY | $9.26 | 1,295,896 | $11,999,997 | 2,595,996 | +99.7% |
| 2021-03-24 00:04 | 2021-03-22 | N/A | N/A | Ostrover Douglas I | Director, 10% owner | Other | BUY | $9.26 | 1,295,896 | $11,999,997 | 2,595,996 | +99.7% |
| 2021-03-23 23:30 | 2021-03-19 | SLDB | Solid Biosciences Inc. | RA CAPITAL MANAGEMENT, L.P. | Director, 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $5.75 | 2,206,685 | $12,688,439 | 10,916,567 | +25.3% |
| 2021-03-24 00:30 | 2021-03-19 | RUBY | N/A | Flagship Ventures Fund IV General Partner LLC | 10% owner | Other | BUY | $29.00 | 210,000 | $6,090,000 | 2,633,703 | +8.7% |
| 2021-03-24 00:19 | 2021-03-23 | SLDB | Solid Biosciences Inc. | PERCEPTIVE ADVISORS LLC | Director, 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $5.75 | 2,608,695 | $14,999,996 | 13,412,552 | +24.1% |
| 2021-03-24 00:05 | 2021-03-22 | N/A | N/A | LIPSCHULTZ MARC S | 10% owner | Other | BUY | $9.26 | 1,295,896 | $11,999,997 | 2,595,996 | +99.7% |
| 2021-03-22 22:21 | 2021-03-19 | SAII | N/A | Mithaq Capital SPC | 10% owner | Other | BUY | $10.50 | 369,924 | $3,884,202 | 4,778,961 | +8.4% |
| 2021-03-22 19:40 | 2021-03-18 | TPGY | N/A | TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 10% owner | Other | BUY | $19.47 | 275,000 | $5,353,288 | 4,810,466 | +6.1% |
| 2021-03-20 02:56 | 2021-03-17 | THRY | Thryv Holdings, Inc. | Walsh Joe | Director, Officer - CEO and President | Services-Advertising | BUY | $18.67 | 200,000 | $3,734,000 | 200,000 | +100.0% |
| 2021-03-20 00:25 | 2021-03-17 | CDMO | N/A | Bamforth Mark R | Director | Other | BUY | $18.18 | 126,000 | $2,290,680 | 126,000 | +100.0% |
| 2021-03-20 01:08 | 2021-03-17 | AIV | Apartment Investment and Management Company | CONSIDINE TERRY | Director - Director | Real Estate Investment Trusts | BUY | $5.72 | 300,000 | $1,714,500 | 300,000 | +100.0% |
| 2021-03-18 19:38 | 2021-03-17 | SAII | N/A | Mithaq Capital SPC | 10% owner | Other | BUY | $10.42 | 255,627 | $2,663,633 | 4,628,870 | +5.8% |
| 2021-03-18 23:06 | 2020-03-11 | MBIN | Merchants Bancorp | O'Brien Patrick D. | Director | State Commercial Banks | BUY | $25.04 | 164,000 | $4,106,199 | 120,000 | +100.0% |
| 2021-03-18 23:43 | 2021-03-16 | RXDX | N/A | Cormorant Asset Management, LP | Other | Other | BUY | $19.00 | 375,000 | $7,125,000 | 2,223,022 | +20.3% |
| 2021-03-19 04:29 | 2021-03-16 | TPGY | N/A | TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 10% owner | Other | BUY | $19.72 | 553,156 | $10,907,130 | 4,535,466 | +13.9% |
| 2021-03-19 00:18 | 2021-03-16 | MRKR | Marker Therapeutics, Inc. | Walker Paul Edward | 10% owner | Pharmaceutical Preparations | BUY | $1.75 | 5,714,285 | $9,999,999 | 10,714,285 | +114.3% |
| 2021-03-19 00:17 | 2021-03-16 | MRKR | Marker Therapeutics, Inc. | Sonsini Peter W. | 10% owner | Pharmaceutical Preparations | BUY | $1.75 | 5,714,285 | $9,999,999 | 10,714,285 | +114.3% |
| 2021-03-19 00:17 | 2021-03-16 | MRKR | Marker Therapeutics, Inc. | SANDELL SCOTT D | 10% owner | Pharmaceutical Preparations | BUY | $1.75 | 5,714,285 | $9,999,999 | 10,714,285 | +114.3% |
| 2021-03-19 00:16 | 2021-03-16 | MRKR | Marker Therapeutics, Inc. | MAKOWER JOSHUA | 10% owner | Pharmaceutical Preparations | BUY | $1.75 | 5,714,285 | $9,999,999 | 10,714,285 | +114.3% |
| 2021-03-19 00:15 | 2021-03-16 | MRKR | Marker Therapeutics, Inc. | Makhzoumi Mohamad | 10% owner | Pharmaceutical Preparations | BUY | $1.75 | 5,714,285 | $9,999,999 | 10,714,285 | +114.3% |
Institutional Conviction in Form 4
Tracking these institutional-scale purchases allows you to follow the "smart money" when their conviction is highest. When an executive or a 10% beneficial owner commits a seven-figure sum to an open-market transaction, it bypasses the routine noise of stock-based compensation. These trades are often a precursor to major corporate developments or a signal that management views the current market valuation as significantly disconnected from the company’s internal growth trajectory. By monitoring these high-value entries, investors can align their portfolios with the capital of those who possess the most intimate understanding of a business's long-term health and potential.
Filtering the Market Noise
Our platform is designed to eliminate the noise and focus strictly on high-impact accumulation from directors and CEOs betting big on their company’s future. The SEC EDGAR database is frequently flooded with thousands of automated Form 4 filings, many of which involve small, technical, or pre-scheduled trades that offer little predictive value for the average investor. By applying a strict $1,000,000 minimum threshold, we isolate the transactions where insiders are taking substantial personal financial risk. This high-conviction filter serves as a powerful transparency tool, identifying the exact moments when corporate leadership moves away from passive ownership toward aggressive capital deployment.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.